Format

Send to

Choose Destination
See comment in PubMed Commons below
Expert Opin Investig Drugs. 2009 Apr;18(4):417-31. doi: 10.1517/13543780902773410 .

Pharmacological therapy for atrial fibrillation: current options and new agents.

Author information

1
University of Washington, Division of Cardiology/Cardiac Electrophysiology, Seattle, WA 98195-6422, USA. viswanam@u.washington.edu

Abstract

Atrial fibrillation is the most commonly encountered cardiac arrhythmia and is directly or indirectly responsible for considerable mortality, morbidity and health care burden. The available medical therapy is limited by marginal efficacy, end-organ toxicity, as well as the potential for undesired ventricular proarrhythmia. Elucidation of the potential mechanisms that underlie the development of atrial fibrillation may provide new targets for drugs that circumvent the problems associated with current medical options. This review focuses on the current and potential future pharmacological agents directed at rhythm control and maintenance of sinus rhythm.

PMID:
19278302
DOI:
10.1517/13543780902773410
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Support Center